Friday, August 21, 2020 - One of the country's largest health care providers has stepped up and saved the day for HIV treatment and prophylactic Truvada users by announcing that they will cover a patient's cost of purchasing generic Truvada alternatives. HIV Plus Mag.com is telling readers that United Health Care will no longer cover the expense of purchasing Descovy but will cover all out-of-pocket costs of generic Truvada. According to HIV Plus Mag.com, "A major health insurer has notified policyholders that it will no longer cover Gilead Sciences’ drug Descovy for pre-exposure prophylaxis, or PrEP, and will instead require them to switch to Truvada, starting September 1." United will cover all out of pocket costs to purchase generic Truvada when the medication becomes available on September 30, 2020. "Gilead said it had reached an agreement to allow Teva Pharmaceuticals to launch generic versions of Truvada (emtricitabine/tenofovir disoproxil fumarate; FTC/TDF) and Atripla (FTC/TDF/efavirenz) on Sept. 30, 2020," according to Healio.com. if you or a loved one have suffered from Truvada side effects leading to broken bones or death you may consider speaking with a Truvada lawsuit attorney, many of which offer a free consultation without obligation.
The move by United Health Care could lead other health care providers to follow suit and cover the previously prohibitive cost of Truvada. Thousands more HIV positive patients may now have access to the drug that could help them to manage their AIDS progression. Covering the cost of Truvada generic drugs may thwart Gilead Science's marketing scheme to seamlessly replace Truvada with Descovy to lockout competition for generic competitors. Gilead agreed to provide millions of bottles of Truvada to patients that qualified for them free of charge as part of President Trump's initiative to wipe out AIDS within ten years.
Truvada patients had been priced out of the Truvada market by the drug's $1800 monthly cost plus the additional $4-500 cost of medical services that are required as a condition. Gilead Sciences CEO Daniel O'Day argued before Congress that the company is justified in charging $20,000 per year for the daily dose of Truvada. He told Congress that the price reflects the company's total research and development expenses needed to discover and produce new and effective drugs, most of which never make it to market. Congress pressed the company to relinquish Truvada's patent to the American Taxpayer and give away Truvada for free since the drug was discovered using US grants.
Gilead had attempted to pull a fast one on patients by giving away Truvada, whose patent was expiring, and then switching it with Descovy without telling patients. Truvada patients have reported significant life-threatening side effects like ketoacidosis, bone fragility and breakages, and kidney and liver damage requiring dialysis and transplants. Many have filed suit alleging that Gilead deliberately kept Descovy, which experts consider to be just as effective as Truvada and much safer, off of the market until Truvada's patent expired to hinder generic competition that would lower the price to pennies per dosage.
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.